PhD-trained biopharmaceutical executive with nearly 30 years of experience shaping R&D portfolio strategy, enterprise governance, and late‑stage development decisions across global pharmaceutical, biotechnology organizations and many global filings of NDAs/BLAs. Trusted advisor to CEOs, Boards, and Investment Committees, with repeated accountability for program prioritization, capital deployment, risk governance, and value inflection decisions from IND through NDA/BLA and commercialization.
Deep expertise integrating scientific, regulatory, and financial perspectives to drive portfolio outcomes in oncology, rare disease, infectious disease, CV/Met, and device‑drug combinations. Proven leader in building and transforming PMOs, portfolio operating models, and cross‑functional decision frameworks to enable speed, accountability, and strategic clarity at scale. Open to full-time, fractional and temp work.
In final stages of aliyah. Posted address and phone are that of one of two sons who has already made aliyah and two more children who are coming soon.
